For an excellent read on MSTX please go to the StockTwits board and check out the post by UnrealMachine.
Time of post Sept 5 4:50 PM. The link is to a google document. Well worth reading especially if you are a
long. Yahoo will not allow a link to be posted. Just deleted my preceding post with link.
Don't have an account there yet either. Will likely get one. Some useful info on the stocktwits board even as there are many who are amateurs and post rubbish. rhodeyred123 for example posts informative stuff and he is worth checking out.. blinkx90 who wrote the highly informative piece on MSTX that I reposted on Yahoo finance a few weeks ago is also there occasionally. Blink's twitter account (@blinkx90) is a good source of info. Good luck.
Ditto. Great research. Request you to kindly post the same on Stocktwits. Many have migrated from the Yahoo message board following the unwelcome change in format. I have been a long term Yahoo finance user but have been forced to move on. Thanks again for the info. I think there are many on Stocktwits who will greatly appreciate your post.
Thanks for your comments which are always appreciated. Unlike other biotech companies in phase 3, we know that Firpdase works and had an excellent chance for approval had management not rushed to file and then file an incomplete NDA . 3,4 DAP remains as sure a bet as possible for an eventual FDA approval. Let us hope for positive developments on the horizon. The last earnings announcement for Q1 was on May 10 followed by the earnings call the next day. We should here soon about the Q2 earnings date soon and likely to be held around Aug 10. we should get a bump up in prices in anticipation of clarity on the revised trial protocol.
Btw, if you have an interest, take a look at MSTX. Risky play as usual given that it is a low priced biotech. The stock dropped sharply on Tuesday as the company announced a further delay in reporting phase 3 for their EPIC trial. The stock has recovered but a further, say 20% appreciation (to mid-0.40s) into the results now scheduled for September is within reach. If the phase 3 results are positive, MSTX should move up sharply.
One does not need to hold into the results if unsure. Also, PTX is worth looking at. Steve Cohen bought into the company recently as he did with CPRX. PTX has strong institutional ownership in general at around 64% and is a possible buyout candidate. As always, please be careful.
Many Yahoo users have shifted to stocktwitsDOTcom. An investor with username RhodeyRed123 claims to have had a phone conversation with CEO Brian Culley following the announcement of the delay in EPIC results to September. The poster has tweeted the gist of hi conversation in 25 tweets. Tweet #1 begins at 8:56 PM on July 26, 2016. Please go to the stocktwits site and type in RhodeyRed123 in the search field to the top right (symbol or username) and then scroll down to the aforementioned time--8:56 PM 7/26/2016.
The person who posted seems sincere and the conversation may well have taken place even as one cannot say for sure or take message boards for granted.
And here is what Pearson has to say:
“I continue to believe in Valeant, Joe and the rest of the management team,” stated Pearson in a prepared statement. “While I trimmed my ownership position for personal reasons, I plan on holding my remaining shares until the company recovers and returns to being traded on fundamentals.”
"Pearson's share sale were to satisfy tax obligations with respect to the 2015 margin sale conducted by Goldman Sachs and for additional liquidity, the company said."
The offer was likely made sometime in the March--April period and more likely in March. VRX was trading in the mid 30's to high 60's during that time and likely the latter when the offer was made. Are we to assume that Takeda and TPG did not do their homework and were simply in an intoxicated gambling mode? Highly unlikely especially given Takeda's experience in the market place. Andrew Left may have made some astute investment decisions in the past but that does not make him infallible as am sure he himself will agree. Sure, investors can choose to follow him. But then again investors can also decide, when there is maximum fear as is the case presently, to do otherwise. VRX is being heavily manipulated currently. Experienced traders and larger players with holding power benefit in this game at the expense of smaller investors like many of us on these message boards. Part of that game is to instill fear amid volatility. Pearson and Left are being conveniently utilized to do precisely that, ie. instill fear. We know what the negatives are ad nauseum and I cannot prophesy where the price will be in the next few days or even weeks. What I do know is when there is so much attempt at manipulation, I am willing to take the risk and stay long. What's the cliche, "when others fear....?
Highly unlikely. Stock trades on NYSE, not Nasdaq. NYSE does not delist stocks trading below $1. Notice that MSTX has been trading below $1 and has not received any delisting notification. Therefore, a reverse split is unlikely. And this is precisely one important reason I intend to hold on to MSTX even in the unlikely event of a less than optimum EPIC outcome. The trials for heart efficacy will continue and the stock will rebound from any potential sell-off especially in light of the already depressed price levels. Emerging biotechs are inherently risky but as has been pointed out by others, the risk/reward looks promising.
Without risk, one cannot expect potential multi bagger returns. GL
Suddenly about Left shorting gets coverage when there are significant near term catalysts pending:
Recall Analyst Ram Selvaraju: "Selvaraju points to three regulatory decisions in the company’s pipeline over the next few weeks that, if approved, could significantly improve Valeant’s bottom line." July 19th is one date.
Please read the article and lest we forget, Selvaraju has a $90 price target.